{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T05:15:28Z","timestamp":1783401328434,"version":"3.54.6"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T00:00:00Z","timestamp":1778630400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T00:00:00Z","timestamp":1778630400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["22K09411"],"award-info":[{"award-number":["22K09411"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["24K19636"],"award-info":[{"award-number":["24K19636"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s10067-026-08170-3","type":"journal-article","created":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T14:01:54Z","timestamp":1778680914000},"page":"3995-4004","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Lower odds of prevalent vertebral fractures with b\/tsDMARD use among rheumatoid arthritis patients in clinical remission: a retrospective observational study"],"prefix":"10.1007","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7071-5667","authenticated-orcid":false,"given":"Yu","family":"Yamashita","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-6610-901X","authenticated-orcid":false,"given":"Kazuhiro","family":"Maeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asami","family":"Zenitani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuru","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,13]]},"reference":[{"key":"8170_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/nrdp.2018.1","volume":"4","author":"JS Smolen","year":"2018","unstructured":"Smolen JS, Aletaha D, Barton A et al (2018) Rheumatoid arthritis. Nat Rev Dis Prim 4:1\u201323. https:\/\/doi.org\/10.1038\/nrdp.2018.1","journal-title":"Nat Rev Dis Prim"},{"key":"8170_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23052871","volume":"23","author":"K Maeda","year":"2022","unstructured":"Maeda K, Yoshida K, Nishizawa T et al (2022) Inflammation and bone metabolism in rheumatoid arthritis: molecular mechanisms of joint destruction and pharmacological treatments. Int J Mol Sci 23:2871. https:\/\/doi.org\/10.3390\/ijms23052871","journal-title":"Int J Mol Sci"},{"key":"8170_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-022-20016-x","volume":"12","author":"S Moshayedi","year":"2022","unstructured":"Moshayedi S, Tasorian B, Almasi-Hashiani A (2022) The prevalence of osteoporosis in rheumatoid arthritis patient: a systematic review and meta-analysis. Sci Rep 12:1\u201311. https:\/\/doi.org\/10.1038\/s41598-022-20016-x","journal-title":"Sci Rep"},{"key":"8170_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10061241","volume":"10","author":"Y Tanaka","year":"2021","unstructured":"Tanaka Y (2021) Managing osteoporosis and joint damage in patients with rheumatoid arthritis: an overview. J Clin Med 10:1241. https:\/\/doi.org\/10.3390\/jcm10061241","journal-title":"J Clin Med"},{"key":"8170_CR5","doi-asserted-by":"publisher","first-page":"3104","DOI":"10.1002\/art.22117","volume":"54","author":"TP Van Staa","year":"2006","unstructured":"Van Staa TP, Geusens P, Bijlsma JWJ et al (2006) Clinical assessment of the long-term risk of fracture in patients with rheumatoid arthritis. Arthritis Rheum 54:3104\u20133112. https:\/\/doi.org\/10.1002\/art.22117","journal-title":"Arthritis Rheum"},{"key":"8170_CR6","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1002\/1529-0131(200003)43:3<522::AID-ANR7>3.0.CO;2-Y","volume":"43","author":"G Haugeberg","year":"2000","unstructured":"Haugeberg G, Uhlig T, Falch JA et al (2000) Bone mineral density and frequency of osteoporosis in female patients with rheumatoid arthritis: Results from 394 patients in the Oslo County rheumatoid arthritis register. Arthritis Rheum 43:522\u2013530. https:\/\/doi.org\/10.1002\/1529-0131(200003)43:3%3c522::AID-ANR7%3e3.0.CO;2-Y","journal-title":"Arthritis Rheum"},{"key":"8170_CR7","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1001\/jama.285.6.785","volume":"285","author":"NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy","year":"2001","unstructured":"NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy (2001) Osteoporosis prevention, diagnosis, and therapy. JAMA 285:785\u2013795. https:\/\/doi.org\/10.1001\/jama.285.6.785","journal-title":"JAMA"},{"key":"8170_CR8","doi-asserted-by":"publisher","unstructured":"Yamashita Y, Hayashi M, Liu A et al (2025) Fam102a translocates Runx2 and Rbpjl to facilitate Osterix expression and bone formation. Nat Commun 16. https:\/\/doi.org\/10.1038\/s41467-024-55451-z","DOI":"10.1038\/s41467-024-55451-z"},{"key":"8170_CR9","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1177\/0004563217733500","volume":"55","author":"I Knani","year":"2018","unstructured":"Knani I, Bouzidi H, Zrour S et al (2018) Increased serum concentrations of N\u025b-carboxymethyllysine are related to the presence and the severity of rheumatoid arthritis. Ann Clin Biochem 55:430\u2013436. https:\/\/doi.org\/10.1177\/0004563217733500","journal-title":"Ann Clin Biochem"},{"key":"8170_CR10","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1080\/14397595.2016.1213943","volume":"27","author":"T Okano","year":"2017","unstructured":"Okano T, Inui K, Tada M et al (2017) High frequency of vertebral fracture and low bone quality in patients with rheumatoid arthritis\u2014results from TOMORROW study. Mod Rheumatol 27:398\u2013404. https:\/\/doi.org\/10.1080\/14397595.2016.1213943","journal-title":"Mod Rheumatol"},{"key":"8170_CR11","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1007\/s00774-025-01597-9","volume":"43","author":"T Mochizuki","year":"2025","unstructured":"Mochizuki T, Yano K, Otani N et al (2025) Association between vertebral fractures and comorbidities in patients with rheumatoid arthritis: a cross-sectional study. J Bone Miner Metab 43:402\u2013410. https:\/\/doi.org\/10.1007\/s00774-025-01597-9","journal-title":"J Bone Miner Metab"},{"key":"8170_CR12","first-page":"73","volume":"26","author":"Y Kageyama","year":"2008","unstructured":"Kageyama Y, Takahashi M, Ichikawa T et al (2008) Reduction of oxidative stress marker levels by anti-TNF-\u03b1 antibody, infliximab, in patients with rheumatoid arthritis. Clin Exp Rheumatol 26:73\u201380","journal-title":"Clin Exp Rheumatol"},{"key":"8170_CR13","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/s00296-007-0419-1","volume":"28","author":"Y Kageyama","year":"2008","unstructured":"Kageyama Y, Takahashi M, Nagafusa T et al (2008) Etanercept reduces the oxidative stress marker levels in patients with rheumatoid arthritis. Rheumatol Int 28:245\u2013251. https:\/\/doi.org\/10.1007\/s00296-007-0419-1","journal-title":"Rheumatol Int"},{"key":"8170_CR14","doi-asserted-by":"publisher","unstructured":"Arakawa S, Shinohara A, Arimura D et al (2025) An automated algorithm for quantitative morphometry of thoracic and lumbar vertebral bodies in lateral radiographs. JBMR Plus 9. https:\/\/doi.org\/10.1093\/jbmrpl\/ziaf017","DOI":"10.1093\/jbmrpl\/ziaf017"},{"key":"8170_CR15","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1007\/BF01623275","volume":"3","author":"EV McCloskey","year":"1993","unstructured":"McCloskey EV, Spector TD, Eyres KS et al (1993) The assessment of vertebral deformity: a method for use in population studies and clinical trials. Osteoporos Int 3:138\u2013147. https:\/\/doi.org\/10.1007\/BF01623275","journal-title":"Osteoporos Int"},{"key":"8170_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1210\/endocr\/bqac126","volume":"163","author":"Y Yamashita","year":"2022","unstructured":"Yamashita Y, Hayashi M, Saito M et al (2022) Osteoblast lineage cells-derived Sema3A regulates bone homeostasis independently of androgens. Endocrinology 163:1\u20137. https:\/\/doi.org\/10.1210\/endocr\/bqac126","journal-title":"Endocrinology"},{"key":"8170_CR17","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.cca.2019.08.012","volume":"498","author":"Y Nishizawa","year":"2019","unstructured":"Nishizawa Y, Miura M, Ichimura S et al (2019) Executive summary of the Japan Osteoporosis Society Guide for the use of Bone Turnover Markers in the diagnosis and treatment of osteoporosis (2018 Edition). Clin Chim Acta 498:101\u2013107. https:\/\/doi.org\/10.1016\/j.cca.2019.08.012","journal-title":"Clin Chim Acta"},{"key":"8170_CR18","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1681\/asn.v991681","volume":"9","author":"S Sugiyama","year":"1998","unstructured":"Sugiyama S, Miyata T, Ueda Y et al (1998) Plasma levels of pentosidine in diabetic patients: an advanced glycation end product. J Am Soc Nephrol 9:1681\u20131688. https:\/\/doi.org\/10.1681\/asn.v991681","journal-title":"J Am Soc Nephrol"},{"key":"8170_CR19","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1056\/nejm199902113400607","volume":"340","author":"C Gabay","year":"1999","unstructured":"Gabay C, Kushner I (1999) Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 340:448\u2013454. https:\/\/doi.org\/10.1056\/nejm199902113400607","journal-title":"N Engl J Med"},{"key":"8170_CR20","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1136\/rmdopen-2016-000382","volume":"3","author":"RM Fleischmann","year":"2017","unstructured":"Fleischmann RM, Van Der Heijde D, Gardiner PV et al (2017) DAS28-CRP and DAS28-ESR cut-offs for high disease activity in rheumatoid arthritis are not interchangeable. RMD Open 3:2\u20136. https:\/\/doi.org\/10.1136\/rmdopen-2016-000382","journal-title":"RMD Open"},{"key":"8170_CR21","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1136\/ard.2006.054205","volume":"66","author":"E Inoue","year":"2007","unstructured":"Inoue E, Yamanaka H, Hara M et al (2007) Comparison of Disease Activity Score (DAS)28- erythrocyte sedimentation rate and DAS28- C-reactive protein threshold values. Ann Rheum Dis 66:407\u2013409. https:\/\/doi.org\/10.1136\/ard.2006.054205","journal-title":"Ann Rheum Dis"},{"key":"8170_CR22","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1006\/bbrc.1998.8203","volume":"244","author":"T Miyata","year":"1998","unstructured":"Miyata T, Ishiguro N, Yasuda Y et al (1998) Increased pentosidine, an advanced glycation end product, in plasma and synovial fluid from patients with rheumatoid arthritis and its relation with inflammatory markers. Biochem Biophys Res Commun 244:45\u201349. https:\/\/doi.org\/10.1006\/bbrc.1998.8203","journal-title":"Biochem Biophys Res Commun"},{"key":"8170_CR23","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/s00296-004-0518-1","volume":"26","author":"GE Hein","year":"2005","unstructured":"Hein GE, K\u00f6hler M, Oelzner P et al (2005) The advanced glycation end product pentosidine correlates to IL-6 and other relevant inflammatory markers in rheumatoid arthritis. Rheumatol Int 26:137\u2013141. https:\/\/doi.org\/10.1007\/s00296-004-0518-1","journal-title":"Rheumatol Int"},{"key":"8170_CR24","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-026-00847-0","author":"H Okabe","year":"2026","unstructured":"Okabe H, Maeda K, Yamashita Y et al (2026) Biologic therapy is associated with faster bone union after the Sauv\u00e9-Kapandji procedure in patients with rheumatoid arthritis. Rheumatol Ther. https:\/\/doi.org\/10.1007\/s40744-026-00847-0","journal-title":"Rheumatol Ther"},{"key":"8170_CR25","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1007\/s00198-023-06816-5","volume":"34","author":"H Hagino","year":"2023","unstructured":"Hagino H, Moriwaki K, Wada T et al (2023) Urinary pentosidine level is associated with the risk of fracture in community-dwelling older adults: a prospective observational study. Osteoporos Int 34:1703\u20131709. https:\/\/doi.org\/10.1007\/s00198-023-06816-5","journal-title":"Osteoporos Int"},{"key":"8170_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/jbm4.10673","volume":"6","author":"S Tanaka","year":"2022","unstructured":"Tanaka S, Saito M, Hagino H et al (2022) Association of urinary pentosidine levels with the risk of fractures in patients with severe osteoporosis: The Japanese Osteoporosis Intervention Trial-05 (JOINT-05). JBMR Plus 6:1\u201310. https:\/\/doi.org\/10.1002\/jbm4.10673","journal-title":"JBMR Plus"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-026-08170-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-026-08170-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-026-08170-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T04:27:14Z","timestamp":1783398434000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-026-08170-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,13]]},"references-count":26,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["8170"],"URL":"https:\/\/doi.org\/10.1007\/s10067-026-08170-3","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,13]]},"assertion":[{"value":"4 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki and was approved by the Ethics Review Committee of Jikei University Hospital (Approval Nos. 35\u2013060 (11683) and 37\u2013050 (12687)). Informed consent was obtained using an opt-out approach.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"M.S. has a patent application pending related to the AI software used in this study. The software was developed in collaboration with Shimadzu Corporation. The other authors have disclosed no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}